

## DuChemBio Co. Ltd. and Life Molecular Imaging SA sign a Manufacturing and Supply Agreement for Alzheimer's Disease Diagnostic Radiopharmaceutical for the Philippines

SEOUL, July 09, 2019 –DuChemBio Co. Ltd. (DCB) and Life Molecular imaging SA (LMI) today announced that both companies have agreed to enter into an exclusive negotiation on manufacturing and supply agreement to introduce the diagnostic imaging radiopharmaceutical NeuraCeq™ ([<sup>18</sup>F]florbetaben, FBB) to the Philippines. The diagnostic radiopharmaceutical is planned to be produced by Khealth Corporation situated at the National Kidney and Transplant Institute, Quezon City, Philippines, which is a subsidiary of DCB.

NeuraCeq™ is an approved drug in the US, EU, Korea and other territories. It is the first diagnostic radiotracer in The Philippines that when used in combination with positron emission tomography (PET) imaging, can identify beta-amyloid plaques in the human brain, to support the early diagnosis of Alzheimer's disease.

Like many other countries, the Philippines has been undergoing an epidemiological transition caused by lifestyles and behaviors associated with industrial and economic development leading to dramatic increase in the prevalence of devastating diseases including Alzheimer's disease which was reported as the 6<sup>th</sup> leading cause of death in the country. With the advent of this new drug introduction in the Philippines, it can increase awareness among Filipinos to diagnose the disease early on and in such be able to customize patient care.

"This agreement between DuChemBio and Life Molecular Imaging is one of the key initiatives that aims for the expansion of promising radiotracers to the Southeast Asian countries that have large potential markets in the future. Not only will NeuraCeq™ enter the Philippine market, but this amyloid radiotracer will come in one package together with FP-CIT (Parkinson disease diagnosis), F-DOPA (Brain tumor diagnosis), and FES (Breast cancer diagnosis) which are new drugs owned by DuChemBio. To build a solid market, it is very important for DuChemBio to be able to export the four radiopharmaceuticals jointly to the Philippines" said Mr. Kim Jongwoo, President and CEO of DuChemBio.

"The Philippines has a growing number of elderly people who are at risk of having Alzheimer's Disease (AD); however there is no available tracer that can accurately detect  $\beta$ -amyloid plaques in the brain. The execution of this agreement will enable us to introduce NeuraCeq™ to the Filipino community. This is a game changer for the Filipino Alzheimer's society. Clinicians can have greater knowledge and assurance in the diagnosis, patients on the other hand can obtain

customized care and confidence in their diagnosis and treatment solutions. Global pharmaceutical companies can also take advantage of the Philippine market to conduct global clinical trials which also provides great opportunity to the Filipino AD patients. “ said Mr. Jaeki Park, Vice President of DuChemBio and Chairman of Khealth Corporation.

## About NeuraCeq™

### Indication and Important Safety Information

NeuraCeq™ is a radiopharmaceutical for diagnostic use indicated for Positron Emission Tomography (PET) imaging of beta-amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD) and other causes of cognitive impairment. NeuraCeq™ should be used in conjunction with a clinical evaluation. A negative scan indicates sparse or no plaques, which is not consistent with a diagnosis of AD. For the limitations in the interpretation of a positive scan, please refer to the approved product information.

The efficacy of NeuraCeq™ for predicting development of AD or monitoring response to therapy has not been established. NeuraCeq™ images should only be interpreted by readers trained in the interpretation of PET images with NeuraCeq™. Following training, image reading errors (including false positive or false negative interpretation of NeuraCeq™ images) may still occur. Administration of NeuraCeq™, as with other radiopharmaceuticals, results in a low amount of ionizing radiation exposure and appropriate safety precautions should be taken to avoid unintentional radiation exposure. The most common side effects observed in clinical trials were injection site pain and injection site erythema.

## About DuChemBio Co., Ltd.

Established in 2002, DuChemBio is the largest radiopharmaceutical firm and the undisputed leader in the field of oncology and neurology PET imaging tracers in Korea. As a pioneer of a fully integrated business model, DuChemBio, develops, obtains regulatory approvals, manufactures, sells and promotes PET radiopharmaceutical solutions to Nuclear Medicine and referring physicians and hence contributes to an early and most accurate diagnosis of life-threatening diseases. DuChemBio's broad portfolio includes FDG for cancer diagnosis, FP-CIT for the diagnosis of Parkinson's disease and NeuraCeq™ for Imaging of patients suspected to suffer from Alzheimer's disease. Khealth Corporation is a subsidiary of DuChemBio in the Philippines which started its operation in November 2015.

## About Life Molecular Imaging

LMI (formerly Piramal Imaging) was formed in 2012 with the acquisition of the molecular imaging research and development portfolio of Bayer Pharma AG, and is now part of the Alliance Medical Group, an integrated business including research and development laboratories, a network of cyclotrons, radiopharmacies and imaging facilities. By developing novel PET tracers for molecular imaging, LMI is focusing on a key field of modern medicine. LMI strives to be a leader in the Molecular Imaging field by developing innovative products that improve early detection and characterization of chronic and life-threatening diseases, leading to better therapeutic outcomes and improved quality of life.

Contacts:

### **Life Molecular Imaging**

Nicole Fletcher | Marketing Communications | Life Molecular Imaging

Tel#: 857-202-1122 | [n.fletcher@life-mi.com](mailto:n.fletcher@life-mi.com)

<https://life-mi.com>

### **DuChemBio Co., Ltd.**

Kini S. Kim | Director of Development and Planning Department

Tel#: 822-332 4868 | [kini.kim@duchembio.com](mailto:kini.kim@duchembio.com)

[www.duchembio.com](http://www.duchembio.com)